These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia. Landgraf H, Grützmacher P, Garcia-Bartels C, Bergmann M, Ehrly AM, Schoeppe W. Eur J Med; 1993 Sep; 2(7):393-7. PubMed ID: 8258026 [Abstract] [Full Text] [Related]
11. Recombinant human erythropoietin in renal transplant recipients with renal anemia. Traindl O, Barnas U, Franz M, Falger S, Klauser R, Kovarik J, Graf H. Clin Transplant; 1994 Feb; 8(1):45-8. PubMed ID: 8136567 [Abstract] [Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [Abstract] [Full Text] [Related]
15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators. Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340 [Abstract] [Full Text] [Related]
16. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A. Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [Abstract] [Full Text] [Related]
17. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H, Wang SX. Blood Purif; 2008 Mar; 26(2):151-6. PubMed ID: 18212498 [Abstract] [Full Text] [Related]
19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators. Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286 [Abstract] [Full Text] [Related]